S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$3.20
+0.16 (+5.26%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.06
$3.36
50-Day Range
$3.04
$5.14
52-Week Range
$2.96
$18.69
Volume
2.15 million shs
Average Volume
1.87 million shs
Market Capitalization
$599.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
311.5% Upside
$13.17 Price Target
Short Interest
Bearish
9.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.90mentions of Nektar Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$573,306 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

393rd out of 1,095 stocks

Pharmaceutical Preparations Industry

175th out of 547 stocks

NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Nektar Therapeutics (NASDAQ:NKTR) Hits New 1-Year Low at $3.02
Nektar Therapeutics (NKTR)
Nektar Therapeutics Presents Data for...
Nektar: Time To Abandon Ship
Nektar promotes internal executive to CFO role
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
8/04/2022
Today
10/02/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$13.17
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+311.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-523,840,000.00
Net Margins
-544.77%
Pretax Margin
-544.42%

Debt

Sales & Book Value

Annual Sales
$101.91 million
Book Value
$3.68 per share

Miscellaneous

Free Float
181,071,000
Market Cap
$599.68 million
Optionable
Optionable
Beta
1.16

Social Links


Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 69)
    CEO, Pres & Director
    Comp: $2.14M
  • Mr. Mark A. Wilson (Age 50)
    Chief Legal Officer & Sec.
    Comp: $798.26k
  • Dr. Jonathan Zalevsky Ph.D.Dr. Jonathan Zalevsky Ph.D. (Age 47)
    Sr. VP & Chief R&D Officer
    Comp: $1.16M
  • Mr. John P. NorthcottMr. John P. Northcott (Age 44)
    Strategic Consulting Advisor
    Comp: $1.07M
  • Ms. Jillian B. ThomsenMs. Jillian B. Thomsen (Age 56)
    Chief Financial Officer
  • Mr. Robert Bacci
    Sr. VP of HR & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Bus. Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 56)
    M.D., Chief Devel. Officer
  • Dr. Brian L. Kotzin M.D. (Age 73)
    Chief Medical Officer
  • Dr. Kevin Brodbeck Ph.D.
    Sr. VP of Technical Operations













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2022?

13 equities research analysts have issued twelve-month price objectives for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $3.00 to $54.00. On average, they predict the company's stock price to reach $13.17 in the next year. This suggests a possible upside of 311.5% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2022?

Nektar Therapeutics' stock was trading at $13.51 at the start of the year. Since then, NKTR stock has decreased by 76.3% and is now trading at $3.20.
View the best growth stocks for 2022 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.16. The biopharmaceutical company had revenue of $21.59 million for the quarter, compared to the consensus estimate of $22.75 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 82.40% and a negative net margin of 544.77%. Nektar Therapeutics's revenue for the quarter was down 23.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.69) earnings per share.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $3.20.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $599.68 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.